Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting

January 16, 2024

By Gregory Gan, MD, PhD
Alykhan Nagji, MD

Opinion

Video

Vinay Raja, MD, explores the crucial role of adjuvant immunotherapy in resectable stage III NSCLC, providing insights into patient selection criteria, considerations for choosing among available treatment options, and the impact of recent trial data updates on informing treatment decisions in this evolving therapeutic landscape.

EP: 1.Available Treatment Options for Patients With Stage-III Resectable NSCLC

EP: 2.Determining Eligibility for Surgical Resection in NSCLC

EP: 3.Expert Perspectives on Perioperative Immunotherapy in Resectable Stage-III NSCLC

Now Viewing

EP: 4.Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting

EP: 5.Treatment Strategies for NSCLC Following Progression on Adjuvant Immunotherapy

EP: 6.Approaches to Treatment and Staging in Unresectable NSCLC

EP: 7.Sequential and Concurrent Chemoradiotherapy in Unresectable Stage-III NSCLC

EP: 8.Expert Insights on Adjuvant Immunotherapy in Unresectable Stage-III NSCLC

EP: 9.Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations

EP: 10.The Potential Role of Combination Adjuvant Immunotherapy in NSCLC

EP: 11.Insights into Strategies Using Concurrent Immunotherapy with Chemoradiotherapy

EP: 12.Clinical Pearls for Treating NSCLC: Insights from Experts at the University of Kansas

EP: 13.Case 1: 72-Year-Old Former Smoker with Stage-IIIA NSCLC and PD-L1 of 90%

EP: 14.Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%

EP: 15.Case 3: 70-Year-Old Former Smoker with Stage IIIB NSCLC with PD-L1 10%

EP: 16.Case 4: 71-Year-Old Diagnosed with Stage IIIA NSCLC Experiencing Pneumonitis After Chemo-IO Treatment

EP: 17.A Multidisciplinary Approach to Treating Resectable NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!